IMPROVEMENT IN IIEF-5 SCORE AFTER INTRACAVERNOSAL INJECTION OF PLATELET RICH PLASMA IN MALES WITH MILD AND MODERATE ERECTILE DYSFUNCTION

Abstract

Objectives: This study aimed to evaluate the effect of intracavernosal PRP injections on erectile function, measured by IIEF-5 scores, EHS scores, and SEP2 and SEP-3 questionnaire outcomes, in males with mild to moderate erectile dysfunction. Study Design and Setting: A quasi-experimental study conducted at the Armed Forces Institute of Urology, Rawalpindi, from June 2024 to February 2025. Methods: The study included n=200 sexually active males aged 40-70 years, divided into two equal groups. One group-A received intracavernosal PRP injections, while the other group-B received placebo treatment. A second PRP injection was administered four weeks after the first. Efficacy was assessed through changes in IIEF-5, EHS, and SEP-2 and SEP-3 scores. Results: The average age of participants was 46.7 years. PRP group-A treatment resulted in a significant improvement in erectile function, with IIEF-5 scores increasing by 2.6 points and EHS scores improving by 0.8 points (P < 0.000). SEP-2 success rates rose to 78% in the PRP group-A, compared to 32% in the placebo group-B, and SEP-3 success rates were 72% in the PRP group-A versus 29% in the placebo group-B. Adverse events were minimal, with only mild penile discomfort in 8% of participants and hematomas in 2%. Conclusion: Intracavernosal PRP injections significantly improve erectile function and sexual performance in men with mild to moderate ED, with minimal adverse effects.